logo-loader
RNS
SkinBioTherapeutics PLC

SkinBioTherapeutics - Directorate change

RNS Number : 8023J
SkinBioTherapeutics PLC
25 June 2026
 

A blue text on a white background Description automatically generated 

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company" or the "Group")

 

Directorate Change

 

25 June 2026 - SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, announces that Emily Bertram, Chief Financial Officer, has decided to leave the business on 30 June 2026.

 

During her tenure, Emily has demonstrated the highest standards of professionalism, integrity and leadership, and has made a significant contribution to the Company's financial stewardship and governance.  She was instrumental in identifying and escalating the issues to the Board regarding the former CEO's conduct and she has worked closely with Alyson Levett and Rachel Parsonage to ensure the business continues to operate as usual. She is ensuring an orderly handover before her departure.   

 

The Company has engaged an Interim CFO, on a non-Board basis, who brings extensive experience as a Chartered Accountant and AIM-listed plc CFO, including a demonstrable track record in strengthening financial controls, corporate governance and reporting standards.  The process for hiring a new permanent CFO is underway. 

 

The Board wishes to express its gratitude for Emily's dedication and commitment, and extends its best wishes for her future career.

-Ends-

 

For more information please contact:

SkinBioTherapeutics plc
Alyson Levett, Interim Chair
Rachel Parsonage, Interim CEO

ir@skinbiotix.com

 

Singer Capital Markets (Nominated Adviser & Broker)
Alex Bond
Sara Hale
Patrick Weaver

+44 (0) 020 7496 3000

 

Vigo Consulting
Melanie Toyne-Sewell, Rozi Morris

+44 (0) 20 7390 0230
SkinBio@vigoconsulting.com


Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life sciences company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Company's strategic approach to skin health is via two routes - tackling skin issues from the 'outside in' and the 'inside out'. The 'outside in' approach is represented by topical creams, and from the 'inside out', via oral supplement solutions which impact the skin via different axes such as the gut and the brain.

SkinBio's products and services are developed through evidence-based science and commercially focused innovation with the aim of supporting skin health, well-being, repair and beauty. SkinBio also has a contract manufacturing and distribution arm related to skin health and other healthcare products.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.SkinBioTherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOADZGZVGKLGVZM
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read